When Eating Becomes Difficult: Students Rethink Cooking During Cancer Treatment
When cancer treatment makes eating difficult, small changes can make a difference. Discover how students from Croatia and North Macedonia are combi...
New Hope for Pancreatic Cancer as Daraxonrasib Nears EU Approval
Daraxonrasib has received a positive European recommendation for previously treated metastatic pancreatic cancer, following trial results showing l...
From the Other Side of the Laboratory Door
After undergoing pancreatic cancer treatment, Pamela stepped inside the laboratory through VOICE-Ireland. She reflects on learning the science behi...
Funding Member Organisations to Make a Greater Impact Across Europe
DiCE’s 2026 operational grants and Wolfram Nolte Memorial Award offer Member Organisations flexible funding to strengthen patient-led work across...
A Stronger Voice for Cholangiocarcinoma: Welcoming Cholangiocarcinoma Ireland to DiCE
Cholangiocarcinoma Ireland has joined DiCE, bringing lived experience, patient advocacy and a strong rare cancer perspective to our European commun...
Strengthening the Voice of Liver Cancer Patients: Welcoming the Croatian Rare Liver Foundation to DiCE
The Croatian Rare Liver Foundation has joined DiCE, strengthening the voice of people affected by liver cancer in Croatia. Its expertise in patient...
How US Drug Pricing Could Affect Access to Cancer Medicines in Europe
US drug pricing reforms could influence when and where cancer medicines reach European patients. Evidence remains inconclusive, but concerns over d...
When Every Month Matters, Innovation Must Reach Patients
Pamela reflects on the promise of daraxonrasib for people living with pancreatic cancer, the urgent need to turn scientific progress into timely an...
From Patient Voice to Global Action: DiCE at ILCA 2026
At ILCA 2026, DiCE joined global liver cancer advocates to advance patient empowerment, responsible innovation, earlier diagnosis and equitable car...